![]() |
|
|
Vol. 290, Issue 3, 935-939, September 1999
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana
Recently, several novel approaches to the treatment of migraine
have been advanced, including selective 5-hydroxytryptamine (or
serotonin) 1B/1D (5-HT1B/1D) receptor agonists
such as sumatriptan and 5-HT1F receptor agonists such
as LY344864. Many 5-HT1B/1D receptor agonists have
been identified based on their ability to produce cerebral vascular
contraction, whereas LY344864 was identified as an inhibitor of
trigeminal nerve-mediated dural extravasation. In our study, several
triptan derivatives were compared with LY344864 for their ability to
contract the rabbit saphenous vein, a tissue used in the preclinical
identification of sumatriptan-related agonists. Sumatriptan,
zolmitriptan, rizatriptan, and naratriptan all contracted the rabbit
saphenous vein from baseline tone, whereas LY344864 in concentrations
up to 10
4 M did not contract the rabbit saphenous vein.
Furthermore, vascular contractions to sumatriptan were markedly
augmented in the presence of prostaglandin F2
(PGF2
). However, even in the presence of
PGF2
(3 × 10
7 M), LY344864 did not
contract the rabbit saphenous vein in concentrations well in excess of
its 5-HT1F receptor affinity
(pKi = 8.2). Only when concentrations
exceeded those likely to activate 5-HT1B and 5-HT1D receptors (>10
5 M) did modest
contractile responses occur in the presence of PGF2
. Use
of these serotonergic agonists revealed a significant correlation
between the contractile potency in the rabbit saphenous vein and the
affinities of these agonists at 5-HT1B and
5-HT1D receptors, although contractile agonist potencies
were not quantitatively similar to 5-HT1B or
5-HT1D receptor affinities. In contrast, no significant
correlation existed between the contractile potencies of these
serotonergic agonists in the rabbit saphenous vein and their affinity
at 5-HT1F receptors. These data support the contention that
activation of 5-HT1F receptors will not result in vascular contractile effects.
This article has been cited by other articles:
![]() |
A. Bhattacharya, K. W. Schenck, Y.-C. Xu, L. Nisenbaum, E. Galbreath, and M. L. Cohen 5-Hydroxytryptamine1B Receptor-Mediated Contraction of Rabbit Saphenous Vein and Basilar Artery: Role of Vascular Endothelium J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 825 - 832. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Watts Serotonin-Induced Contraction in Mesenteric Resistance Arteries: Signaling and Changes in Deoxycorticosterone Acetate-Salt Hypertension Hypertension, March 1, 2002; 39(3): 825 - 829. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. McKune and S. W. Watts Characterization of the Serotonin Receptor Mediating Contraction in the Mouse Thoracic Aorta and Signal Pathway Coupling J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 88 - 95. [Abstract] [Full Text] |
||||